logo

Europe Oral Anti-Diabetic Drug Market Size (2024 - 2029)

The Europe Oral Anti-Diabetic Drug Market is anticipated to experience growth over the forecast period, driven by various factors including the impact of the COVID-19 pandemic on diabetes management. The pandemic highlighted the vulnerabilities of diabetes patients, leading to increased attention and support for their medication needs. This situation, coupled with the rising prevalence of diabetes across Europe, is expected to contribute to the expansion of the market. The market's growth trajectory reflects the ongoing demand for medications that help regulate blood glucose levels and manage diabetes-related health issues.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Diabetes Care Drugs Research Europe Oral Anti-Diabetic Drug Market Market Size

Market Size of Europe Oral Anti-Diabetic Drug Industry

Europe Oral Anti-Diabetic Drug Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Market Size (2024) USD 7.36 Billion
Market Size (2029) USD 8.70 Billion
CAGR (2024 - 2029) 3.40 %

Major Players

Europe Oral Anti-Diabetic Drug Market Major Players

*Disclaimer: Major Players sorted in no particular order

Europe Oral Anti-Diabetic Drug Market Analysis

The Europe Oral Anti-Diabetic Drug Market size is estimated at USD 7.36 billion in 2024, and is expected to reach USD 8.70 billion by 2029, growing at a CAGR of 3.40% during the forecast period (2024-2029).

The COVID-19 epidemic significantly influenced the European Diabetes Medicines Market. As people with diabetes already have weakened immune systems, COVID-19 causes those immune systems to deteriorate rapidly. Compared to healthy persons, those with diabetes are more likely to experience significant complications. During COVID-19, the makers of diabetes pharmaceuticals took special care to ensure that diabetic patients received their meds with the assistance of local governments. On their website, NovoNordisk stated that they "continue to provide our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses.

Pharmaceuticals known as diabetic medications were created to stabilize and regulate blood glucose levels in diabetics. Diabetes patients infected with SARS-CoV-2 during the COVID-19 pandemic may be treated with diabetic medications. The estimated cost per hospital admission for type 2 diabetes patients with good glycemic control during the first wave of COVID-19 in Europe ranged from EUR 25,018 to EUR 57,244 for type 1 diabetes patients with poor glycemic control, reflecting a higher risk of intensive care, ventilator support, and a longer hospital stay. Those without diabetes were expected to pay EUR 16,993. For COVID-19 secondary care, 13.9 billion euros in direct costs were projected to be spent overall in Europe. Hence, diabetes treatment accounted for 23.5% of overall costs.

In recent years, diabetes prevalence has increased alarmingly throughout the European continent. Many health issues are related to diabetes. Diabetes patients need to make several adjustments throughout the day to keep their blood glucose levels within normal ranges. For example, they may need to administer more insulin or consume more carbohydrates.

As a result of the aforementioned variables, it is projected that the market under study will expand during the course of the investigation.

Europe Oral Anti-Diabetic Drug Industry Segmentation

Antihyperglycemic medications are taken orally to lower blood glucose levels. They are frequently employed in the management of type 2 diabetes. The Europe Oral Anti-Diabetic Drug Market is set to witness a CAGR of more than 3% during the forecast period. The Europe Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), and Geography. The report offers the value (in USD million) and volume (in Units million) for the above segments.

Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)
Biguanides
Metformin
Alpha-Glucosidase Inhibitors
Alpha-Glucosidase Inhibitors
Dopamine D2 receptor agonist
Bromocriptin
SGLT-2 inhibitors
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
DPP-4 inhibitors
Onglyza (Saxagliptin)
Tradjenta (Linagliptin)
Vipidia/Nesina(Alogliptin)
Galvus (Vildagliptin)
Sulfonylureas
Sulfonylureas
Meglitinides
Meglitinides
Geography
France (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Germany (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Italy (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Russia (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Spain (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
United Kingdom (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Rest of Europe (Value and Volume 2017-2028)
By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)
Need A Different Region Or Segment?
Customize Now

Europe Oral Anti-Diabetic Drug Market Size Summary

The European oral anti-diabetic drug market is poised for steady growth over the forecast period, driven by the increasing prevalence of diabetes across the continent. The market is characterized by a rising demand for medications that help manage blood glucose levels, particularly in the context of an aging population and lifestyle-related health issues. The COVID-19 pandemic highlighted the critical role of these medications, as individuals with diabetes faced heightened health risks. This situation underscored the importance of ensuring continuous access to diabetes treatments, with pharmaceutical companies like NovoNordisk playing a pivotal role in maintaining supply chains and supporting healthcare professionals. The market is dominated by well-established drugs such as metformin, which remains a first-line treatment due to its proven efficacy, safety, and cost-effectiveness. The availability of oral anti-diabetic medications, which are often preferred over insulin due to their ease of use and lower cost, further supports market expansion.

Germany is expected to lead the market, driven by a high prevalence of diabetes and a robust healthcare infrastructure that supports the management of the disease. The country's focus on high-quality care and the introduction of new therapeutic options are key factors contributing to market growth. The German market benefits from stringent pricing and reimbursement policies, which ensure access to necessary treatments. The presence of major pharmaceutical companies like Eli Lilly, AstraZeneca, and Sanofi, alongside innovative developments such as Oramed's oral insulin capsule, highlights the competitive landscape of the market. These companies are actively engaged in research and development to introduce new products and enhance treatment options for diabetes patients. As the market continues to evolve, the emphasis on innovation and collaboration is expected to drive further growth and improve patient outcomes across Europe.

Explore More

Europe Oral Anti-Diabetic Drug Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

    3. 1.3 Market Restraints

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Bargaining Power of Suppliers

      2. 1.4.2 Bargaining Power of Consumers

      3. 1.4.3 Threat of New Entrants

      4. 1.4.4 Threat of Substitute Products and Services

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 Oral Anti-diabetic drugs (Value and Volume, 2017 - 2028)

      1. 2.1.1 Biguanides

        1. 2.1.1.1 Metformin

      2. 2.1.2 Alpha-Glucosidase Inhibitors

        1. 2.1.2.1 Alpha-Glucosidase Inhibitors

      3. 2.1.3 Dopamine D2 receptor agonist

        1. 2.1.3.1 Bromocriptin

      4. 2.1.4 SGLT-2 inhibitors

        1. 2.1.4.1 Invokana (Canagliflozin)

        2. 2.1.4.2 Jardiance (Empagliflozin)

        3. 2.1.4.3 Farxiga/Forxiga (Dapagliflozin)

        4. 2.1.4.4 Suglat (Ipragliflozin)

      5. 2.1.5 DPP-4 inhibitors

        1. 2.1.5.1 Onglyza (Saxagliptin)

        2. 2.1.5.2 Tradjenta (Linagliptin)

        3. 2.1.5.3 Vipidia/Nesina(Alogliptin)

        4. 2.1.5.4 Galvus (Vildagliptin)

      6. 2.1.6 Sulfonylureas

        1. 2.1.6.1 Sulfonylureas

      7. 2.1.7 Meglitinides

        1. 2.1.7.1 Meglitinides

    2. 2.2 Geography

      1. 2.2.1 France (Value and Volume 2017-2028)

        1. 2.2.1.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      2. 2.2.2 Germany (Value and Volume 2017-2028)

        1. 2.2.2.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      3. 2.2.3 Italy (Value and Volume 2017-2028)

        1. 2.2.3.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      4. 2.2.4 Russia (Value and Volume 2017-2028)

        1. 2.2.4.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      5. 2.2.5 Spain (Value and Volume 2017-2028)

        1. 2.2.5.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      6. 2.2.6 United Kingdom (Value and Volume 2017-2028)

        1. 2.2.6.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

      7. 2.2.7 Rest of Europe (Value and Volume 2017-2028)

        1. 2.2.7.1 By Drug (Biguanides, Alpha-glucosidase Inhibitors, Dopamine-D2 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides)

Europe Oral Anti-Diabetic Drug Market Size FAQs

The Europe Oral Anti-Diabetic Drug Market size is expected to reach USD 7.36 billion in 2024 and grow at a CAGR of 3.40% to reach USD 8.70 billion by 2029.

In 2024, the Europe Oral Anti-Diabetic Drug Market size is expected to reach USD 7.36 billion.

Europe Oral Anti-Diabetic Drug Report Snapshots

Europe Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)